Cite
HARVARD Citation
Verstovsek, S. et al. (2023). Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study. Lancet. 401 (10373), pp. 269-280. [Online].